Tilray Brands Inc. (TLRY) Options Positioning, Max Pain & Unusual Sweeps

$2.64 -1.86% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.63

Tilray Brands Inc. (TLRY) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $390.2M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TLRY Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is TLRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-01, Tilray Brands Inc. (NASDAQ: TLRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.64 (-1.86% 1D, market cap $390.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLRY ranks #888 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does TLRY compare to OBIO and SNDL in the Health Care sector?
β–Ό

Within the Health Care sector (Medicinal Chemicals and Botanical Products), TLRY carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 28.4%, and ROIC of -3.9%. By comparison, OBIO (Orchestra BioMed Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $366.0M) and SNDL (SNDL Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC β€”, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TLRY?
β–Ό

Per TLRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001731348), Tilray Brands Inc. generated $915.5M in revenue (+11.5% YoY), -$121.4M in net income, and -$69.1M in free cash flow against $2.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.63 (-0.52%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (32/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D
Cash (3)Whales (9)SEC (8)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$16 Bull$2 Base$2 Bear
πŸ“¬ FREE TLRY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for TLRY)Realized 20D OHLCV Swing Band: Β±10.9%
Deterministic 5-Pillar Attribution (32/100 Composite)
πŸ” WHY TLRY SCORES 32/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+10/20 pts (31% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 18.4 (OVERSOLD (<32))

β–² #2 Bullish Driver: Whale & Options Positioning+9/20 pts (28% of score)

20D Institutional Volume Accumulation (Β±10.9% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
40
Grade D$3.54-14.1% Next Q
Q2 (-2Q)
37
Grade E$3.04-7.6% Next Q
Q3 (-1Q)
35
Grade E$2.81-6% Next Q
Current
32
Grade E$2.64-9.2% Hist 90D Ξ±
Trajectory: D (40) β†’ E (32)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a TLRY Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While TLRY currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.79) and Max Pain ($2.77) forces dealer call-delta covering toward $16.48.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TLRYβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œTLRY Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±10.9%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (TLRY)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for TLRY.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TLRY)

  • βœ“Walkthrough of TLRY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TLRY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.69%β–Ό DESCENDING CHANNEL
2026-10-30O $2.65H $2.67L $2.49C $2.64VOL 4.93M
RES: $4.36SUP: $1.72SMA50: $3.79SMA200: $5.47
$10.28$8.17$6.06$3.95$1.83RES $4.36SUP $1.72$2.642026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TLRY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TLRY today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for TLRY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TLRY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TLRY)

1. Head-to-Head Health Care Peer Comparison (TLRY vs. OBIO, SNDL, CGC, USNA)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tilray Brands Inc. (TLRY) ranks #888 by composite RQD confidence (32/100, grade E) and #484 by equity capitalization ($390.2M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. SNDL currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with TLRY at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TLRY ACTIVE
Tilray Brands Inc.
E 32/100 β€” 28.4% -3.9% -1.86% $390.2M Benchmark Subject
OBIO
Orchestra BioMed Holdings Inc.
E 28/100 β€” 96.0% -35.0% +1.67% $366.0M /obio-vs-tlry β†’
SNDL
SNDL Inc.
C- 61/100 β€” β€” β€” +0.78% $316.3M /sndl-vs-tlry β†’
CGC
Canopy Growth Corporation
D 51/100 β€” β€” β€” +0.46% $285.6M /cgc-vs-tlry β†’
USNA
USANA Health Sciences Inc.
C- 61/100 24.6x 78.3% 7.9% -1.91% $265.0M /usna-vs-tlry β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2026-05-31 β€’ CIK 0001731348

In its most recent audited fiscal period (FY2025, filed 2026-05-31), Tilray Brands Inc. (TLRY) reported GAAP revenue of $915.5M (+11.5% vs. FY2024 revenue of $821.3M , and +16.0% cumulative change since FY2023) , GAAP net income of -$121.4M, operating cash flow of -$69.1M, and free cash flow of -$69.1M (+26.9% YoY). On the balance sheet, TLRY closed FY2025 with $2.07B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-05-31 $915.5M -$121.4M -$69.1M -$69.1M $2.07B β€”
FY2024 (FY) 2025-05-31 $821.3M -$2.19B -$94.6M -$94.6M $3.40B β€”
FY2023 (FY) 2024-05-31 $788.9M -$245.0M -$30.9M -$30.9M β€” β€”

3. TLRY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TLRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Tilray Brands Inc. (NASDAQ: TLRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.64 (-1.86% 1D, market cap $390.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TLRY ranks #888 in composite RQD confidence.

How does TLRY compare to OBIO and SNDL in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), TLRY carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 28.4%, and ROIC of -3.9%. By comparison, OBIO (Orchestra BioMed Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $366.0M) and SNDL (SNDL Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC β€”, cap $316.3M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TLRY?

Per TLRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001731348), Tilray Brands Inc. generated $915.5M in revenue (+11.5% YoY), -$121.4M in net income, and -$69.1M in free cash flow against $2.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TLRY trading relative to its 50-day, 200-day, and 52-week technical levels?

TLRY last traded at $2.64 (-1.86% on volume of 4,210,125 shares), positioning the stock -30.34% below its 50-day simple moving average ($3.79) and -51.74% below its 200-day simple moving average ($5.47). Across its 52-week range of $2.49 to $15.70, TLRY sits at the 1.1% percentile with a 14-day RSI of 18.4 (OVERSOLD (<32)) and an implied next-earnings move of Β±10.9% ($2.35 to $2.93).

TLRY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

What is TLRY's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for TLRY.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%